• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

开发含羧酸的口服候选药物的特定“类药性”规则。

Development of specific "drug-like property" rules for carboxylate-containing oral drug candidates.

机构信息

Evotec AG, Hamburg, Germany.

出版信息

ChemMedChem. 2010 Dec 3;5(12):2102-13. doi: 10.1002/cmdc.201000355.

DOI:10.1002/cmdc.201000355
PMID:20979082
Abstract

The carboxylate moiety is an important pharmacophore in the medicinal chemist's arsenal and is sometimes an irreplaceable functionality in drug-target interactions. Thus, practical guidance on its use in the most optimized manner would be a welcome addition to rational drug design. Key physicochemical and ADMET-PK properties from a dataset of drugs containing a carboxylate (COOH) moiety were assembled and compared with those of a broader, general drug dataset. Our main objective was to identify features specific to COOH-containing oral drugs that could be converted into simple rules delineating the boundaries within which prospective COOH-containing chemical series and COOH-containing drug candidates would be reasonably expected to possess properties suitable for oral administration. These specific "drug-like" property rules include molecular weight, the number of rotatable bonds, the number of hydrogen bond donors and acceptors, predictions of lipophilic character (calculated log P and log D values), topological polar surface area (TPSA), and the pK(a) value of the carboxylate moiety. Similar to the various sets of criteria that have emerged over the past decade and which have significantly reshaped the way medicinal chemists think about preferred drug chemical space, we propose these specific COOH "drug-like" property rules as a guide for the design of superior COOH-containing drug candidates and as a tool to better manage the liabilities generally associated with the presence of a COOH moiety.

摘要

羧基部分是药物化学家武器库中的一个重要药效团,有时也是药物-靶标相互作用中不可替代的功能。因此,关于如何以最优化的方式使用羧基的实用指南将是合理药物设计的一个受欢迎的补充。从包含羧基 (COOH) 部分的药物数据集收集关键的物理化学和 ADMET-PK 性质,并将其与更广泛的一般药物数据集进行比较。我们的主要目标是确定 COOH 含有药物特有的特征,这些特征可以转化为简单的规则,划定潜在 COOH 含有化学系列和 COOH 含有候选药物的界限,这些药物合理预期具有适合口服给药的性质。这些特定的“类药性”性质规则包括分子量、旋转键的数量、氢键供体和受体的数量、亲脂性(计算的 logP 和 logD 值)、拓扑极性表面积(TPSA)和羧基部分的 pKa 值。与过去十年中出现的各种标准类似,这些标准极大地改变了药物化学家对首选药物化学空间的思考方式,我们提出这些特定的 COOH“类药性”性质规则作为设计优越的 COOH 含有候选药物的指南,并作为更好地管理与 COOH 部分存在相关的一般负债的工具。

相似文献

1
Development of specific "drug-like property" rules for carboxylate-containing oral drug candidates.开发含羧酸的口服候选药物的特定“类药性”规则。
ChemMedChem. 2010 Dec 3;5(12):2102-13. doi: 10.1002/cmdc.201000355.
2
Escape from flatland: increasing saturation as an approach to improving clinical success.逃离平面世界:提高饱和度作为提升临床成功率的一种方法。
J Med Chem. 2009 Nov 12;52(21):6752-6. doi: 10.1021/jm901241e.
3
[Strategy of molecular design of drugs: the unification of macro-properties and micro-structures of a molecule].[药物分子设计策略:分子宏观性质与微观结构的统一]
Yao Xue Xue Bao. 2008 Mar;43(3):227-33.
4
Designing active template molecules by combining computational de novo design and human chemist's expertise.通过结合计算从头设计和人类化学家的专业知识来设计活性模板分子。
J Med Chem. 2007 Apr 19;50(8):1925-32. doi: 10.1021/jm061356+. Epub 2007 Mar 17.
5
Application of ALOGPS 2.1 to predict log D distribution coefficient for Pfizer proprietary compounds.应用ALOGPS 2.1预测辉瑞专利化合物的log D分配系数。
J Med Chem. 2004 Nov 4;47(23):5601-4. doi: 10.1021/jm049509l.
6
The graphical representation of ADME-related molecule properties for medicinal chemists.为药物化学家提供 ADME 相关分子性质的图形表示。
Drug Discov Today. 2011 Jan;16(1-2):65-72. doi: 10.1016/j.drudis.2010.11.002. Epub 2010 Nov 10.
7
Characteristics of known drug space. Natural products, their derivatives and synthetic drugs.已知药物空间的特征。天然产物、其衍生物和合成药物。
Eur J Med Chem. 2010 Dec;45(12):5646-52. doi: 10.1016/j.ejmech.2010.09.018. Epub 2010 Sep 17.
8
Known drug space as a metric in exploring the boundaries of drug-like chemical space.已知药物空间作为探索类药性化学空间边界的一种度量。
Eur J Med Chem. 2009 Dec;44(12):5006-11. doi: 10.1016/j.ejmech.2009.08.014. Epub 2009 Sep 6.
9
The medicinal chemist's toolbox: an analysis of reactions used in the pursuit of drug candidates.药物化学家的工具箱:对用于研发候选药物的反应的分析
J Med Chem. 2011 May 26;54(10):3451-79. doi: 10.1021/jm200187y. Epub 2011 May 2.
10
In silico prediction of the solubility advantage for amorphous drugs - Are there property-based rules for drug discovery and early pharmaceutical development?非晶态药物溶解度优势的计算机模拟预测——药物发现和早期药物研发中是否存在基于性质的规则?
Eur J Pharm Sci. 2013 Feb 14;48(3):554-62. doi: 10.1016/j.ejps.2012.11.015. Epub 2012 Dec 20.

引用本文的文献

1
Synthesis of Benzoic Acids from Electrochemically Reduced CO Using Heterogeneous Catalysts.使用多相催化剂通过电化学还原CO合成苯甲酸。
ChemSusChem. 2025 Feb 1;18(3):e202401084. doi: 10.1002/cssc.202401084. Epub 2024 Nov 5.
2
Balancing Properties with Carboxylates: A Lead Optimization Campaign for Selective and Orally Active CDK9 Inhibitors.羧酸酯类化合物的性质平衡:选择性及口服活性CDK9抑制剂的先导化合物优化研究
ACS Med Chem Lett. 2021 Jun 22;12(7):1108-1115. doi: 10.1021/acsmedchemlett.1c00161. eCollection 2021 Jul 8.
3
Pharmacokinetics Comparison, Intestinal Absorption and Acute Toxicity Assessment of a Novel Water-Soluble Astragaloside IV Derivative (Astragalosidic Acid, LS-102).
一种新型水溶性黄芪甲苷IV衍生物(黄芪酸,LS-102)的药代动力学比较、肠道吸收及急性毒性评估
Eur J Drug Metab Pharmacokinet. 2019 Apr;44(2):251-259. doi: 10.1007/s13318-018-0515-5.
4
A Review on Platelet Activating Factor Inhibitors: Could a New Class of Potent Metal-Based Anti-Inflammatory Drugs Induce Anticancer Properties?血小板活化因子抑制剂综述:一类新型强效金属基抗炎药物能否诱导抗癌特性?
Bioinorg Chem Appl. 2017;2017:6947034. doi: 10.1155/2017/6947034. Epub 2017 Mar 28.
5
Minimizing the Contribution of Enterohepatic Recirculation to Clearance in Rat for the NCINI Class of Inhibitors of HIV.将肠肝循环对大鼠体内HIV的NCINI类抑制剂清除率的贡献降至最低。
ACS Med Chem Lett. 2014 Apr 16;5(6):711-6. doi: 10.1021/ml500110j. eCollection 2014 Jun 12.
6
The significance of acid/base properties in drug discovery.酸碱性在药物发现中的意义。
Chem Soc Rev. 2013 Jan 21;42(2):485-96. doi: 10.1039/c2cs35348b.
7
6-alkylsalicylates are selective Tip60 inhibitors and target the acetyl-CoA binding site.6-烷基水杨酸盐是选择性的 Tip60 抑制剂,靶向乙酰辅酶 A 结合位点。
Eur J Med Chem. 2012 Jan;47(1):337-44. doi: 10.1016/j.ejmech.2011.11.001. Epub 2011 Nov 10.
8
The influence of the 'organizational factor' on compound quality in drug discovery.“组织因素”对药物发现中化合物质量的影响。
Nat Rev Drug Discov. 2011 Sep 30;10(10):749-65. doi: 10.1038/nrd3552.